Etubics Corporation

Seattle, WA 98119

SBIR Award Summary

Total Number of Awards 14
Total Value of Awards $8.18MM
First Award Date 08/01/06
Most Recent Award Date 09/19/14

Key Personnel

Last Name Name Awards Contact
Gayle Richard B. Gayle 2
Jones Frank R. Jones 12

14 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 09/19/14 - 02/15/15

DESCRIPTION (provided by applicant): With the discovery of new biomarkers associated with tumor development, many of these tumor-associated antigens (TAA) are being utilized in immunotherapeutic modalities designed to induce anti-tumor directed cytotoxic immune responses. It is increasingly clear that not any one of these TAA is sufficient, as ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 09/01/14 - 06/30/15

DESCRIPTION (provided by applicant): The objective of this project is to further develop an immunotherapeutic strategy for HIV-associated malignancy based on the role of HPV in the pathogenesis and perform the pre-clinical experiments with a new drug which allow us to enter clinical trials to test its safety and effectiveness. HPV related cancer...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 07/01/14 - 06/30/15

DESCRIPTION (provided by applicant): The objective of this project is to further develop an immunotherapeutic strategy for HIV-associated malignancy based on the role of HPV in the pathogenesis and perform the pre-clinical experiments with a new drug which allow us to enter clinical trials to test its safety and effectiveness. HPV related cancer...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 07/01/13 - 06/30/14

DESCRIPTION (provided by applicant): The objective of this project is to further develop an immunotherapeutic strategy for HIV-associated malignancy based on the role of HPV in the pathogenesis and perform the pre-clinical experiments with a new drug which allow us to enter clinical trials to test its safety and effectiveness. HPV related cancer...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 07/01/11 - 06/30/12

DESCRIPTION (provided by applicant): The objective of this project is to develop a therapeutic strategy for H|V-associated malignancy based on the role of HPV in the pathogenesis. HPV related cancers express the E6/E7 oncoproteins of HPV that are ideal targets for immune inducing vaccines. We will develop a vaccine based upon a novel adenovirus ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 02/01/11 - 07/31/12

DESCRIPTION (provided by applicant): Current generation Adenovirus (Ad) vector vaccines deleted at the E1 or the E1, E3 regions have resulted in experimental potential to immunize against a variety of infectious diseases such as HIV. These Ad vectors permit the delivery of genes, which express proteins that stimulate the immune system. An advanc...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 08/01/10 - 07/31/12

DESCRIPTION (provided by applicant): The objective of this project is to continue to develop an adenoviral vector vaccine against CEA that is effective in stimulating cell-mediated immune responses in subjects previously immune to Adenovirus. The Ad-CEA vaccine endpoint is to treat patients with CEA bearing cancers. CEA is a tumor associated pr...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-06-134
Budget: 02/01/10 - 01/31/11

DESCRIPTION (provided by applicant): Current generation Adenovirus (Ad) vector vaccines deleted at the E1 or the E1, E3 regions have resulted in experimental potential to immunize against a variety of infectious diseases such as HIV. These Ad vectors permit the delivery of genes, which express proteins that stimulate the immune system. An advanc...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 08/28/09 - 07/31/10

DESCRIPTION (provided by applicant): The objective of this project is to continue to develop an adenoviral vector vaccine against CEA that is effective in stimulating cell-mediated immune responses in subjects previously immune to Adenovirus. The Ad-CEA vaccine endpoint is to treat patients with CEA bearing cancers. CEA is a tumor associated pr...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 04/01/09 - 06/30/10

DESCRIPTION (provided by applicant): The objective of this project is to continue developing an adenoviral serotype 5 (Ad5) vector vaccine against Ad5[E1-, E2b]-Her2/neu that is effective in stimulating cell-mediated immunity (CMI) in animals previously immune to Ad5. The Ad5[E1-, E2b-]- Her2/neu vaccine endpoint is to treat patients with HER2 ...

Load More